Application of asiaticoside in treatment of multi-drug resistant staphylococcus aureus infection
By targeting Centella asiaticin of Staphylococcus aureus aldehyde dehydrogenase, the biosynthesis pathway of Staphylococcus aureus was blocked, and the treatment problem of multidrug-resistant Staphylococcus aureus infection was solved, and effective inhibition of the bacteria was achieved and drug resistance is reduced and has less cytotoxicity to humans.
Patent Information
- Application Number
- CN202410877227.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-02
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art lacks effective strategies for the treatment of multidrug-resistant Staphylococcus aureus infection, especially due to bacterial resistance to vancomycin and drug side effects.
Centella as an inhibitor targeting Staphylococcus aureus aldehyde-based dehydrogenase, block the Staphylococcus flavin biosynthesis pathway, verify its antibacterial potential through high-throughput virtual screening and biological activity detection, and use it Medical preparations are prepared as raw materials to treat multidrug-resistant Staphylococcus aureus infection.
Centella asiaticin significantly inhibits the toxicity and antioxidant ability of multidrug-resistant Staphylococcus aureus, reduces bacterial infectivity, and reduces the production of bacterial resistance without affecting the sub-anti-bacterial concentration of human normal cells. Risk, its antibacterial activity is better than clinical first-line antibiotics.
Smart Images

Figure CN118903160A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to application of asiatica glycoside in treating multidrug-resistant Staphylococcus aureus infection. Background Art
[0002] Staphylococcus aureus belongs to the phylum Firmicutes and is a Gram-positive bacterium that can produce coagulase. At present, about 30-50% of the world's population has asymptomatic colonization of Staphylococcus aureus. This bacterium can colonize and grow continuously on the surface of human skin, gastrointestinal tract or nasopharynx, and reproduce offspring, paving the way for further infection. After being infected by Staphylococcus aureus, the human body may experience a series of clinical symptoms, including skin or soft tissue infection, lung infection, bloodstream infection, infective endocarditis, osteomyelitis, etc., and may even cause sepsis and septicemia, and eventually induce death. Infections caused by Staphylococcus aureus are recurrent, and 8-33% of patients with skin or soft tissue infection and bloodstream infection have repeated symptoms of infection.
[0003] One of the typical characteristics of Staphylococcus aureus is that it can continue to acquire antibiotic resistance as new antibiotics are developed and put into use, thereby evolving into multidrug-resistant strain typing, such as methicillin-resistant Staphylococcus aureus. At present, vancomycin is the first-line drug used in the clinic to treat multidrug-resistant Staphylococcus aureus infections. However, with its strong genetic adaptability to antibiotics, Staphylococcus aureus has also acquired resistance to vancomycin. In addition, vancomycin has obvious toxic side effects, and its nephrotoxicity and ototoxicity are strong. These reasons have led to the current lack of effective strategies in the clinic to treat infections caused by multidrug-resistant Staphylococcus aureus. Therefore, the development of new antibacterial drugs other than antibiotics is particularly important and urgent.
[0004] Neutralizing virulence factors to make bacteria more sensitive to the human immune system and thus achieve antibacterial effects is a potential new antibacterial strategy that can effectively reduce the development of bacterial resistance. Staphylococcus aureus aldehyde dehydrogenase (SaAldH) is an important member of the biosynthetic pathway of the key virulence factor staphyloxanthin. Therefore, screening new antibacterial drugs targeting SaAldH can reduce bacterial toxicity by blocking the biosynthetic pathway of staphyloxanthin, thereby achieving an antibacterial effect, and can reduce the risk of bacterial resistance and reduce the side effects of drugs, bringing convenience to clinical treatment.
[0005] Asiaticoside is the dried whole herb of Centella asiatica, a plant of the genus Centella in the family Apiaceae. It is one of the main components of triterpenoid saponins in Centella asiatica extract. Modern pharmacological studies have confirmed that asiaticoside has the effects of inhibiting scar formation, promoting wound healing, anti-tumor, neuroprotection, antianxiety, and immunomodulation. However, there is no information on the application of asiaticoside in the treatment of multidrug-resistant Staphylococcus aureus infection. Summary of the invention
[0006] The purpose of the present invention is to provide an application of asiatica glycoside in treating multidrug-resistant Staphylococcus aureus infection.
[0007] In order to achieve the above object, the present invention provides the use of Centella asiatica in treating multidrug-resistant Staphylococcus aureus infection.
[0008] Furthermore, Centella asiatica glycoside targets Staphylococcus aureus aldehyde dehydrogenase, inhibits enzyme activity, blocks the staphyloxanthin biosynthesis pathway, and reduces bacterial toxicity.
[0009] Furthermore, a high-throughput virtual screening method was used to screen for the strong binding of Centella asiatica glycoside to the Staphylococcus aureus aldehyde dehydrogenase target, which has antibacterial potential.
[0010] Furthermore, the blocking of the synthetic pathway comprises the following verification steps: d Value and IC 50 The specific binding of asiatica glycoside to the target SaAldH was detected by value characterization. Then, the bacteria were treated with asiatica glycoside at a sub-inhibitory concentration and cultured for a period of time, and then the biosynthesis of staphyloxanthin in the bacteria was detected by thin layer chromatography.
[0011] Furthermore, the antibacterial ability of the Centella asiatica glycoside includes the following verification steps: detecting the antibacterial biological activity of Centella asiatica glycoside in vitro and in vivo through minimum inhibitory concentration value determination, bacterial growth curve determination and mouse systemic infection model.
[0012] Furthermore, Centella asiatica glycoside reduces the antioxidant capacity of multidrug-resistant Staphylococcus aureus, reduces its infectivity at sub-inhibitory concentrations that do not affect bacterial growth, and reduces the risk of bacterial resistance.
[0013] Furthermore, the effect of the Centella asiatica glycoside on the antioxidant capacity of multidrug-resistant Staphylococcus aureus was verified by using hydrogen peroxide oxidation stress experiment and macrophage phagocytosis experiment.
[0014] Furthermore, asiatica glycoside has low toxicity to normal human cells and can effectively protect normal human cells during bacterial infection.
[0015] Furthermore, verifying the toxic effect of the Centella asiatica glycoside on normal human cells includes the following steps: using VeroE6 cells as the research object, infecting multidrug-resistant Staphylococcus aureus and then observing the apoptosis of the cells through drug treatment, and detecting the cytotoxicity of Centella asiatica glycoside.
[0016] The present invention also provides an application of Centella asiatica in treating multidrug-resistant Staphylococcus aureus infection. The medicine for treating multidrug-resistant Staphylococcus aureus infection uses Centella asiatica as a raw material, and is added with medically acceptable adjuvants or auxiliary ingredients to prepare a medical preparation for treating multidrug-resistant Staphylococcus aureus infection.
[0017] The present invention has the following advantages:
[0018] The present invention screens out asiaticoside with antibacterial potential. Asiaticoside has a very obvious inhibitory effect on the enzyme activity of SaAldH, blocks the pigment synthesis pathway of multidrug-resistant Staphylococcus aureus, thereby reducing the generation of virulence factor staphyloxanthin and reducing bacterial toxicity.
[0019] The present invention verifies that asiatica glycoside has good antibacterial activity, especially has good inhibitory effect on multidrug-resistant Staphylococcus aureus, and its inhibitory effect is better than the clinical first-line antibiotics vancomycin and linezolid.
[0020] The present invention verifies that asiatica glycoside can significantly reduce the antioxidant capacity of bacteria and reduce its infectivity at a sub-inhibitory concentration that does not affect the growth of bacteria, thereby reducing the risk of bacterial resistance.
[0021] The present invention verifies that the toxicity of asiatica glycoside to normal human cells is lower than that of clinical first-line antibiotics, and can effectively protect normal human cells during bacterial infection. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] The accompanying drawings are used to provide a further understanding of the present invention and constitute a part of the specification. Together with the embodiments of the present invention, they are used to explain the present invention and do not constitute a limitation of the present invention. In the accompanying drawings:
[0023] Figure 1 is the docking binding site of high-throughput virtual screening in Example 1;
[0024] Figure 2 The results of the antibacterial activity test of Centella asiatica in Example 2, (A) MIC value, (B) bacterial growth curve, (C) mouse systemic infection model;
[0025] Figure 3 The results of the verification of the inhibition of SaAldH enzyme activity by asiatica glycoside in Example 3, thereby blocking the synthesis of staphyloxanthin, (A) the dissociation constant K d Value representation, (B)IC50 Value, (C) Thin layer chromatography to detect pigment synthesis;
[0026] Figure 4 The verification results of Example 4 that asiatica glycoside reduces the antioxidant capacity of bacteria and thus reduces the risk of bacterial resistance, (A) hydrogen peroxide oxidation stress experiment, (B) macrophage phagocytosis experiment;
[0027] Figure 5 These are the experimental results of the inhibition of bacterial infection of cells by Centella asiatica in Example 5. DETAILED DESCRIPTION
[0028] The present invention will now be further described in detail with reference to the accompanying drawings, but it should be understood that the protection scope of the present invention is not limited by the specific embodiments.
[0029] The present invention provides an application of asiatica glycoside in treating multidrug-resistant Staphylococcus aureus infection.
[0030] According to a specific embodiment of the present invention, the use of Centella asiatica in the treatment of multidrug-resistant Staphylococcus aureus infection, Centella asiatica targets Staphylococcus aureus aldehyde dehydrogenase, inhibits enzyme activity, blocks the staphyloxanthin biosynthesis pathway, and reduces bacterial toxicity.
[0031] Furthermore, a high-throughput virtual screening method was used to screen for the strong binding of Centella asiatica glycoside to the Staphylococcus aureus aldehyde dehydrogenase target, which has antibacterial potential.
[0032] Furthermore, the high-throughput virtual screening method comprises:
[0033] The SaAldH protein was expressed and purified using conventional molecular biology and biochemical methods, and the protein structure of SaAldH was analyzed by structural biology. After that, high-throughput rapid virtual screening was performed using AutodockVina. In order to improve the clinical application prospects of the candidate compounds screened, the compound library was selected from DrugBankFDA listed drug library, Selleck's clinical phase I post-drug library, inhibitor library, food and drug homologous compound library, human endogenous metabolite library, intestinal flora metabolite library, known active compound library and anti-infective compound library. The screening results showed that the compound with the highest docking score was Centella asiatica.
[0034] In order to verify that Centella asiatica glycoside blocks the biosynthesis pathway of staphyloxanthin, the present invention includes the following verification steps: d Value and IC 50 The value was used to characterize the specific binding of Centella asiatica glycoside to the target. Then, the bacteria were treated with Centella asiatica glycoside at a sub-inhibitory concentration and cultured for a period of time. The synthesis of staphyloxanthin in the bacteria was detected by thin layer chromatography.
[0035] Furthermore, the present invention provides a series of methods for detecting the biological activity of Centella asiatica glycoside, using tryptone soy broth (TSB) culture medium for experiments.
[0036] To verify the antibacterial potential of asiaticaoside, the present invention includes the following verification steps: detecting the antibacterial biological activity of asiaticaoside in vitro and in vivo through minimum inhibitory concentration (MIC) value determination, bacterial growth curve determination and mouse systemic infection model.
[0037] Furthermore, the antibacterial effect of asiatica glycoside was compared with that of clinical first-line antibiotics.
[0038] Furthermore, the clinical first-line antibiotics include linezolid or vancomycin.
[0039] Furthermore, Centella asiatica glycoside reduces the antioxidant capacity of multidrug-resistant Staphylococcus aureus, reduces its infectivity at sub-inhibitory concentrations that do not affect bacterial growth, and reduces the risk of bacterial resistance.
[0040] Furthermore, the effect of the Centella asiatica glycoside on the antioxidant capacity of multidrug-resistant Staphylococcus aureus was verified by using hydrogen peroxide oxidation stress experiment and macrophage phagocytosis experiment.
[0041] Furthermore, the effect of Centella asiatica on the antioxidant capacity of bacteria was evaluated by comparing the survival rates of bacteria treated with and without drug treatment under oxidative stress.
[0042] Furthermore, asiatica glycoside has low toxicity to normal human cells and can effectively protect normal human cells during bacterial infection.
[0043] In order to verify the cytotoxicity of Centella asiatica glycoside to normal human cells, the following steps are included: VeroE6 cells are used as the research object, multidrug-resistant Staphylococcus aureus is infected, and then the cell apoptosis is observed through drug treatment, and the cytotoxicity of Centella asiatica glycoside is detected.
[0044] According to a specific embodiment of the present invention, the use of Centella asiatica in the treatment of multidrug-resistant Staphylococcus aureus infection is prepared by using Centella asiatica as a raw material and adding medically acceptable excipients or auxiliary ingredients to prepare a medical preparation for the treatment of multidrug-resistant Staphylococcus aureus infection.
[0045] The application of asiatica glycoside of the present invention in treating multidrug-resistant Staphylococcus aureus infection is described in more detail below by way of specific examples. It should be understood that the present invention is not limited thereto.
[0046] Example 1 High-throughput virtual screening of new antibacterial drugs based on SaAldH structure
[0047] In the docking virtual screening experiment, the dimer structure of SaAldH was used as the protein receptor, and the DrugBankFDA listed drug library, Selleck's clinical phase I post-drug library, inhibitor library, food and drug homologous compound library, human endogenous metabolite library, intestinal flora metabolite library, known active compound library and anti-infective compound library were selected as ligand molecule libraries. Before docking, water molecules and small molecules in the protein receptor structure were deleted, molecules containing metal ions, ions, salts, etc. in the ligand molecule library were deleted, and the compounds in the library were merged and deduplicated. The software used in the docking experiment was Autodock Vina. During the docking process, the protein structure was converted into a PDBQT file, which contains all polar residues with hydrogen, and the ligand was also converted into a PDBQT file and all bonds were set to be rotatable. During docking, the protein was fixed and the ligand was set to have a certain flexibility. This flexible docking calculation was performed using the Lamarckian genetic algorithm. Residues A61, T62, I66, Y116, Q119, T243, C244, V245, M395, L397, A398, F404 of the A chain of the receptor protein and Y92, L93, H442, I453, F456, F457, K449-N459 of the C chain form the binding pocket for small molecules in the receptor protein, e.g. Figure 1 As shown, the docking box parameters corresponding to the binding pocket are set as follows: the box center coordinates are 20.485, 23.754, 109.476 (corresponding to the coordinates of the x, y, and z axes, in angstroms), and the box size is Autodock Vina automatically calculates the grid map and clusters the docking results. The docking will search for possible conformations of the ligand within the range of the grid box and select the best docking conformation with the lowest binding energy. The final results show that the compound with the highest docking score is Centella asiatica.
[0048] Example 2 Antibacterial activity of asiaticaside
[0049] Determination of the minimum inhibitory concentration (MIC) of drugs against bacteria: dilute the overnight bacteria to the logarithmic phase, and then dilute the bacteria to OD 600 0.05 for standby, take a sterile 96-well plate, dilute the drug with culture medium, and then use the two-fold method to dilute the concentrations to 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125 μg / mL. Add 50 μL of drug to each well and then add 50 μL of diluted bacterial solution, put it in a 37°C incubator and culture it for 20 hours. The culture medium is used as a negative control, and the bacterial solution (without drug) is used as a positive control.
[0050] OD was measured by microplate reader 600Absorption value: Bacterial growth curve determination, pick the monoclonal activated by TSB plate and spot into fresh TSB liquid medium, and culture at 37℃ overnight. The next day, dilute 1:100 into fresh TSB medium and culture for about 2h until OD 600 =1.0(about 10 6 CFU / mL), and then dilute the bacterial solution into fresh culture medium at a ratio of 1:100, mix well and add 1mL of bacteria to each well of a 24-well culture plate. The 24-well culture plate inoculated with the bacterial solution was placed in a multifunctional microplate reader at 37°C and cultured at a shaking rate of 220 rpm for 11 hours. The OD value of the bacterial solution in each well was measured every 1 hour. 600 For the drug-treated group, 2 μg / mL of different drugs were added to the diluted fresh bacterial solution, mixed well, and added to the culture plate at 1 mL of bacteria per well, and the bacterial growth was detected in the same way.
[0051] Determination of antibacterial effect in mouse systemic infection model: Mice infected with Staphylococcus aureus ATCC43300 were divided into four groups, one group was the control group, and the other three groups were treated with 100 mg / kg linezolid, vancomycin and asiaticoside. All mice were female BALB / c, 6-8 weeks old, and weighed 18-22 g. Five days after infection, the liver and lungs of all mice were removed, ground with a tissue grinder, and then graded diluted with PBS, smeared on TSB solid culture medium and colony counted.
[0052] like Figure 2 The results showed that the MIC value determination results showed that Centella asiatica had a significant inhibitory effect on multidrug-resistant Staphylococcus aureus in vitro, and the MIC value was lower than that of the clinical first-line antibiotics vancomycin and linezolid ( Figure 2 A), and further verified the difference in antibacterial effects through bacterial growth curve determination experiment ( Figure 2 B). In addition, the results of constructing a mouse systemic infection model to detect the antibacterial activity of Centella asiatica in vivo showed that Centella asiatica also has a good antibacterial effect in vivo, and its antibacterial ability is better than linezolid at the same dosage concentration ( Figure 2 C).
[0053] Example 3 Inhibition of staphyloxanthin biosynthesis by asiaticaside
[0054] Dissociation constant K d Determination of K value: The K value of asiatica glycoside binding to SaAldH in vitro was determined by surface plasmon resonance (SPR) technology using Biacore T200. dThe value was measured. Using the CM5 amino coupling chip, the multi-cycle kinetic method was adopted to select 8 dilution gradients of small molecules, and the DMSO solvent calibration solution was prepared for the solvent calibration of the instrument. Small molecules of different concentrations were injected in order from low to high concentrations. The program was set to an injection time of 180s, a flow rate of 30μL / min, a dissociation time of 300s, a regeneration time of 30s, and a regeneration solution of glycine-hydrochloric acid, pH = 2.5. After obtaining the sensorgrams of small molecules of different concentrations, the Affinity method was used for fitting analysis.
[0055] The half inhibitory concentration IC of asiaticaside on SaAldH enzyme activity 50 Value determination: Using SaAldH's specific substrate 4,4'-Diapolycopen-4-al as the substrate, the process of SaAldH catalyzing the substrate requires the coenzyme NAD + The reaction product NADH has spectral absorption at 340nm. The amount of NADH produced by a multifunctional microplate reader can reflect the enzyme activity of SaAldH. The data in the linear growth range of the absorption value are fitted to obtain the initial reaction rate v0 value. The relative enzyme activity is obtained by (initial reaction rate of the drug-added group / initial reaction rate of the control group) × 100%. The log value of the drug concentration is the x-axis and the relative enzyme activity is the y-axis. The Graphpad software is used to fit the log (Inhibitor) vs. response–Variable slope (four parameters) equation to obtain the IC 50 value.
[0056] Determination of pigment synthesis by thin layer chromatography: The constructed pETDuet-crtM / crtN plasmid, pACYCDuet-crtP plasmid and pET47b-SaAldH plasmid were co-transfected into Escherichia coli BL21 (DE3) for co-expression, acetone was used to directly extract the pigment from the bacteria, and the pigment composition was analyzed by thin layer chromatography.
[0057] The results of SPR experiments showed that the K of asiatica glycoside binding to the target SaAldH d The value is at the sub-micromolar level, indicating that it binds strongly to the target ( Figure 3 A) IC 50 The results of the value determination showed that the half inhibitory concentration of Centella asiatica to inhibit SaAldH enzyme activity was also at the submicromolar level, indicating that Centella asiatica does have a specific inhibitory effect on the target ( Figure 3 B).
[0058] Further testing of the effect of asiatica glycoside on blocking the biosynthesis of staphyloxanthin by thin layer chromatography showed that after the addition of asiatica glycoside treatment, obvious substrate accumulation occurred in the bacteria, while almost no product generation was observed, indicating that asiatica glycoside successfully blocked the pigment synthesis pathway by inhibiting the activity of SaAldH enzyme, which is also an important mechanism for its antibacterial effect ( Figure 3 C).
[0059] Example 4: Centella asiatica glycoside reduces bacterial antioxidant capacity
[0060] Hydrogen peroxide oxidative stress test: The wild-type S. aureus ATCC43300 strain was cultured in TSB medium at 37°C for 16 h. The drug-added group used a subinhibitory concentration that did not affect bacterial growth, and 0.1 μg / mL of asiaticoside was added. The cells were collected by centrifugation and washed twice with PBS buffer. The cells were then suspended with PBS buffer and the bacterial solution was diluted to 5×10 6 Colony-forming unit (CFU) / mL. No H2O2 was added to the control group, and H2O2 with a final concentration of 10mM was added to the experimental group and incubated at 0℃ in the dark for 45min. Then, catalase with a final concentration of 4U / mL was added and incubated at 37℃ for 20min to terminate the reaction. The bacterial solution was diluted in an appropriate ratio and spread on TSB solid culture medium. After culturing at 37℃ for 16h, the monoclonal spots were counted, and the bacterial survival ability was calculated by (the number of monoclonal spots in the experimental group / the number of monoclonal spots in the control group) × 100%.
[0061] Macrophage phagocytosis assay: Mouse macrophage J774 cell line was cultured in RPMI 1640 medium containing 10% FBS in a 37°C cell culture incubator. J774 cells were plated at approximately 5 × 10 cells per well. 5The density of cells was inoculated into a 24-well plate, and the volume of culture medium per well was 475 μL, and the culture was adherent for 24 hours. The S. aureus ATCC43300 strain was cultured in TSB medium at 37°C to the logarithmic phase, and 0.1 μg / mL asiaticoside was added to the drug-dosed group, and then the bacteria were collected. The bacteria were washed twice with PBS buffer and the bacterial suspension was diluted to 109 CFU / mL. 25 μL of bacterial solution was added to each well of the 24-well plate inoculated with J774 cells, and the 24-well plate was centrifuged at 200×g for 5 minutes, and then placed in a cell culture incubator for 37°C incubation for 30 minutes. The bacterial solution was aspirated and the cells were washed 5 times with PBS buffer, and RPMI 1640 medium containing 200 μg / mL gentamicin was added and continued to be cultured in the cell culture incubator for 1 hour to kill the bacteria that did not enter the macrophages. After removing the culture medium with antibiotics and washing the cells three times with PBS buffer, 300 μL of PBS buffer containing 0.025% saponin was added to each well to lyse the J774 cells. The lysate was diluted in an appropriate ratio and spread on TSB solid culture medium, and the number of colony growth was used to measure the survival ability of bacteria inside macrophages.
[0062] The hydrogen peroxide oxidation stress experiment and macrophage phagocytosis experiment were used to simulate the performance of bacteria in the oxidative stress environment of the human immune system, such as Figure 4 As shown in the figure, after adding centella asiatica, the antioxidant capacity of bacteria decreased significantly, which is consistent with the decrease in antioxidant capacity after the reduction of pigment synthesis in bacteria. The above experimental results show that centella asiatica achieves antibacterial effect by targeting the synthesis pathway of bacterial virulence factors, thereby reducing the antioxidant capacity of bacteria. The risk of bacterial resistance caused by this type of antibacterial drug is significantly lower than that of antibiotics.
[0063] Example 5: Centella asiatica glycoside inhibits bacterial infection of cells
[0064] Multidrug-resistant Staphylococcus aureus was used as the research object to infect VeroE6 cells. First, the VeroE6 cell line was revived and plated after two passages. The cell concentration was 2×10 4 / mL of bacteria were gently spread in the center of the confocal dish, incubated in a 37℃ cell culture incubator for 2h, and then 2-3mL of DMEM medium was added and cultured overnight. The next day, the culture medium in the confocal dish was removed, gently washed twice with PBS, and replaced with culture medium containing 1μg / mL of different drugs. Then, the bacteria pre-cultured with DMEM medium for 2h were diluted to an OD of 0.05 and added to the cells. After incubation for 2h, the changes in cell morphology were recorded by taking pictures. Each group repeated the experiment 3 times independently.
[0065] like Figure 5As shown in the figure, the normal morphology of VeroE6 cells is epithelial cells that grow adherently. When bacteria are added alone for infection, the cells begin to aggregate and die after 2 hours. When 1 μg / mL of asiaticoside is added, the bacterial infection of cells is basically inhibited. In contrast, when the same concentration of linezolid is added, the morphology of VeroE6 cells still changes significantly, indicating that the inhibitory effect of linezolid at this concentration is not good, which shows that the inhibitory effect of asiaticoside on bacterial infection is also better than linezolid. After that, the cytotoxicity of the drug itself was further tested. The results showed that when 1 μg / mL of asiaticoside was added alone, no significant cytotoxicity was shown, while the same concentration of linezolid had caused the death of some VeroE6 cells, indicating that the cytotoxicity of asiaticoside is also less than that of linezolid, and it can accurately target bacteria to prevent cells from being infected.
[0066] Through the evaluation of the above examples, it can be concluded that Centella asiatica has the ability to treat multidrug-resistant Staphylococcus aureus infection.
[0067] The present invention verifies that asiatica glycoside has a very obvious inhibitory effect on the enzyme activity of SaAldH, blocks the pigment synthesis pathway of multidrug-resistant Staphylococcus aureus, thereby reducing the production of virulence factor staphyloxanthin and reducing bacterial toxicity.
[0068] The present invention verifies that asiatica glycoside has good antibacterial activity, especially has good inhibitory effect on multidrug-resistant Staphylococcus aureus, and its inhibitory effect is better than the clinical first-line antibiotics vancomycin and linezolid.
[0069] The present invention verifies that asiatica glycoside can significantly reduce the antioxidant capacity of bacteria and reduce its infectivity at a sub-inhibitory concentration that does not affect the growth of bacteria, thereby reducing the risk of bacterial resistance.
[0070] The present invention verifies that the toxicity of asiatica glycoside to normal human cells is lower than that of clinical first-line antibiotics, and can effectively protect normal human cells during bacterial infection.
[0071] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.
Claims
1. An application of Centella asiatica glycoside in treating multidrug-resistant Staphylococcus aureus infection.
2. The use according to claim 1, characterized in that: Centella asiatica targets the aldehyde dehydrogenase of Staphylococcus aureus, inhibits enzyme activity, blocks the biosynthesis pathway of staphyloxanthin, and reduces bacterial toxicity.
3. The use according to claim 2, characterized in that: A high-throughput virtual screening method was used to screen for strong binding of Centella asiatica glycoside to the Staphylococcus aureus aldehyde dehydrogenase target, which has antibacterial potential.
4. The use according to claim 2, characterized in that: The blocking synthetic pathway comprises the following verification steps: d Value and IC 50 The value was used to characterize the specific binding of Centella asiatica glycoside to the target. Then, the bacteria were treated with Centella asiatica glycoside at a sub-inhibitory concentration and cultured for a period of time. The biosynthesis of staphyloxanthin in the bacteria was detected by thin layer chromatography.
5. The use according to claim 1, characterized in that: The antibacterial ability of the Centella asiatica glycoside includes the following verification steps: detecting the antibacterial biological activity of the Centella asiatica glycoside in vitro and in vivo through minimum inhibitory concentration value determination, bacterial growth curve determination and mouse systemic infection model.
6. The use according to claim 1, characterized in that: Centella asiatica reduces the antioxidant capacity of multidrug-resistant Staphylococcus aureus, reduces its infectivity at sub-inhibitory concentrations that do not affect bacterial growth, and reduces the risk of bacterial resistance.
7. The use according to claim 6, characterized in that: Verification of the effect of the Centella asiatica glycoside on the antioxidant capacity of multidrug-resistant Staphylococcus aureus includes the use of hydrogen peroxide oxidation stress experiments and macrophage phagocytosis experiments.
8. The use according to claim 1, characterized in that: Centella asiatica glycoside has low toxicity to normal human cells and can effectively protect normal human cells during bacterial infection.
9. The use according to claim 8, characterized in that: Verifying the toxic effect of the Centella asiatica glycoside on normal human cells includes the following steps: using VeroE6 cells as the research object, infecting multidrug-resistant Staphylococcus aureus and then observing the apoptosis of the cells through drug treatment, and detecting the cytotoxicity of Centella asiatica glycoside.
10. The use according to claim 1, characterized in that: The application uses Centella asiatica glycoside as a raw material, adds medically acceptable excipients or auxiliary ingredients, and prepares a medical preparation for treating multidrug-resistant Staphylococcus aureus infection.
